Actively Recruiting
AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
Led by Chang Gung Memorial Hospital · Updated on 2025-09-19
100
Participants Needed
1
Research Sites
77 weeks
Total Duration
On this page
Sponsors
C
Chang Gung Memorial Hospital
Lead Sponsor
C
Conmed Pharmaceutical & Bio-Medical Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin®) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study will investigate the potential of AST-120 to reduce the risk of CKD-associated complications, including cardiovascular disease, by reducing PBUT levels in AKD patients.
CONDITIONS
Official Title
AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Diagnosed with acute kidney disease (AKD) stage 2 or 3 based on KDIGO-AKD criteria
- Post-discharge estimated glomerular filtration rate (eGFR) between 30 and 60 ml/min/1.73m8
- Hospitalization duration no longer than 1 month
You will not qualify if you...
- Presence of cancer or hematological malignancies
- AKD causes that require inpatient management (e.g., diabetic foot, obstructive uropathy with sepsis, cirrhosis)
- Being bedridden, needing nasogastric tube feeding, long-term oxygen therapy, or using urinary catheters
- Severe constipation requiring daily use of more than one laxative
- Abnormal liver function (ALT > 5 times upper limit or total bilirubin > 2 mg/dL)
- History of peptic ulcers within the last month
- Pregnancy
- Allergy to AST-120 (Kremezin4)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chang Gung Memorial Hospital, Taoyuan, Taiwan
Taoyuan, Taiwan, 333
Actively Recruiting
Research Team
C
Chih-Hsiang Chang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here